[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346478-105":59,"doc-detail-346478-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","reassessing-onco-exceptionalism-equity-and-resource-allocation-in-immunotherapeutic-cancer-treatments","Reassessing onco-exceptionalism - equity and resource allocation in immunotherapeutic cancer treatments","","Only a small fraction of cancer patients possess specific markers eligible for effective targeted therapies, prompting ethical scrutiny of treating cancer differently through resource allocation. The paper evaluates whether reimbursement of costly drugs under immunotherapeutic precision treatments is equitable. It first situates healthcare resource allocation within immunotherapeutic cancer care, then examines arguments for and against onco-exceptionalism, and concludes by advocating a proactive health approach.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/reassessing-onco-exceptionalism-equity-and-resource-allocation-in-immunotherapeutic-cancer-treatments/346478/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/reassessing-onco-exceptionalism-equity-and-resource-allocation-in-immunotherapeutic-cancer-treatments/346478.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What does onco-exceptionalism mean in this paper?","Question",{"text":113,"@type":114},"Onco-exceptionalism refers to perceiving and treating cancer as distinct from other medical conditions, leading to unique considerations in development, funding, approval processes, drug pricing, and coverage decisions.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why is cost-effectiveness analysis ethically challenged here?",{"text":118,"@type":114},"Although cost-effectiveness analysis aims to maximize overall health gains, it often overlooks distributional effects—who benefits and how resources are allocated—thereby risking health inequities and exclusion of certain groups from reimbursement.",{"name":120,"@type":111,"acceptedAnswer":121},"What are the paper’s main research questions?",{"text":122,"@type":114},"It asks (1) what arguments support and oppose onco-exceptionalism and (2) whether onco-exceptionalism can be justified based on reflections on precision oncology and different approaches to reimbursement decisions, and what form it might take.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},346478,1790823047,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Original research  \nInstitute for the History, Philosophy and Ethics of Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany  \nCorrespondence to  \nDr Hamideh Frühwein; [h.mahdiani@uni-mainz.de](h.mahdiani@uni-mainz.de)  \nReceived 15 January 2025 Accepted 4 April 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.  \nTo cite: Frühwein H, Münch N, Paul NW.  \nJ Med Ethics Epub ahead of print: [please include Day Month Year] . doi:10 . 1136/ jme-2025-110739  \nReassessing onco-exceptionalism: equity and resource allocation in immunotherapeutic cancer treatments  \nHamideh Frühwein  , Nikolai Münch, Norbert W Paul  \nABSTRACT  \nGiven that only a small fraction of patients with cancer exhibits specific markers making them eligible for effective targeted therapies, this paper investigates the justification of treating cancer differently in  \nterms of resource allocation when it comes to the application of novel precise therapies—the so-called onco-exceptionalism. Specifically, it assesses whether the reimbursement of expensive drugs is equitable. To do so, we first contextualise healthcare resource allocation concerning immunotherapeutic treatments for cancer, then explore arguments for and against oncoexceptionalism and finally conclude by advocating for a proactive health approach.  \nINTRODUCTION  \nThe allocation of healthcare resources, particularly in the realm of cancer treatment, poses a significant challenge for policymakers and healthcare providers. Current policy discussions stress the need for more research on the intersection of coverage laws and oncology care.1  \nGiven the finite financial resources in healthcare, the escalating costs of novel cancer treatments inevitably prompt distributional concerns. In addressing these allocation dilemmas, policymakers nowadays heavily rely on cost-effectiveness analysis (CEA). CEA typically involves assessing quality-adjusted life years (QALYs) alongside the incremental costeffectiveness ratio. This method evaluates the financial impact and health benefits of new interventions compared with existing options, guided by society’s willingness to pay (WTP). The WTP threshold isan economic concept used in health economics to determine whether an intervention provides sufficient health benefits to justify its cost. It represents the maximum amount a healthcare system or society is willing to pay for a unit of health benefit (eg, a QALY). If the cost of an intervention is below this threshold, it is considered cost-effective; if it exceeds the threshold, it may not be considered cost-effective.2  \nWhile CEAs are designed to maximise overall health gains (and therefore the overall effectiveness of healthcare spending), the distributional effects (ie, who actually benefits from these health interventions and how resources are distributed across different groups in society) are often overlooked. This omission of distributional concerns does present an ethical challenge, as CEA might unintentionally lead to health inequities. For example, when health insurers, government health bodies and health systems use CEA to decide which treatments  \nto reimburse, certain groups may be excluded. This may be seen as a concomitant bias as illustrated by Loree et al3 and Pierce,4 with an underrepresentation of racial minorities, and by Unger et al5 for patients in low-income communities in certain studies. The advent of immunotherapies and combination therapies in oncology has further complicated this landscape due to a higher level of segmentation of patient groups accompanied by substantially rising costs, a trend that is projected to persist in the foreseeable future.6 This escalation is furthermore attributed to the introduction of new medications, broadening of treatment indicationsand prolonged therapy duration resulting from desirable enhanced patient outcomes.7 Against this context, we would like to pose questions","cbCaieqecouiLrVg","https://ap.wps.com/l/cbCaieqecouiLrVg","pdf",213406,"English","# Abstract\n# Introduction\n## Cost-effectiveness analysis and distributional concerns\n## Cancer-specific policies and onco-exceptionalism\n## Research questions\n# Arguments for and against increasing the threshold\n# Conclusion","[{\"question\":\"What does onco-exceptionalism mean in this paper?\",\"answer\":\"Onco-exceptionalism refers to perceiving and treating cancer as distinct from other medical conditions, leading to unique considerations in development, funding, approval processes, drug pricing, and coverage decisions.\"},{\"question\":\"Why is cost-effectiveness analysis ethically challenged here?\",\"answer\":\"Although cost-effectiveness analysis aims to maximize overall health gains, it often overlooks distributional effects—who benefits and how resources are allocated—thereby risking health inequities and exclusion of certain groups from reimbursement.\"},{\"question\":\"What are the paper’s main research questions?\",\"answer\":\"It asks (1) what arguments support and oppose onco-exceptionalism and (2) whether onco-exceptionalism can be justified based on reflections on precision oncology and different approaches to reimbursement decisions, and what form it might take.\"}]","Reassessing onco-exceptionalism - equity and resource allocation in immunotherapeutic cancer treatments | PDF",1790061615,15,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f287799c20021767c37623b78c9b94c.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20c7b49c9cee7c1995b902a904ca578b.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8c1bd508dc1a1c4ba26cdecbbde5452.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e6e960742b18f093f99251869da455d.webp",980,1306]